Emergent Mind

Abstract

We regularly consider answering counterfactual questions in practice, such as "Would people with diabetes take a turn for the better had they choose another medication?". Observational studies are growing in significance in answering such questions due to their widespread accumulation and comparatively easier acquisition than Randomized Control Trials (RCTs). Recently, some works have introduced representation learning and domain adaptation into counterfactual inference. However, most current works focus on the setting of binary treatments. None of them considers that different treatments' sample sizes are imbalanced, especially data examples in some treatment groups are relatively limited due to inherent user preference. In this paper, we design a new algorithmic framework for counterfactual inference, which brings an idea from Meta-learning for Estimating Individual Treatment Effects (MetaITE) to fill the above research gaps, especially considering multiple imbalanced treatments. Specifically, we regard data episodes among treatment groups in counterfactual inference as meta-learning tasks. We train a meta-learner from a set of source treatment groups with sufficient samples and update the model by gradient descent with limited samples in target treatment. Moreover, we introduce two complementary losses. One is the supervised loss on multiple source treatments. The other loss which aligns latent distributions among various treatment groups is proposed to reduce the discrepancy. We perform experiments on two real-world datasets to evaluate inference accuracy and generalization ability. Experimental results demonstrate that the model MetaITE matches/outperforms state-of-the-art methods.

We're not able to analyze this paper right now due to high demand.

Please check back later (sorry!).

Generate a summary of this paper on our Pro plan:

We ran into a problem analyzing this paper.

Newsletter

Get summaries of trending comp sci papers delivered straight to your inbox:

Unsubscribe anytime.